Understanding Breast Density Reporting: Implications for Family Medicine Clinicians - Abstract
The Food and Drug Administration (FDA) mandated that beginning September 10, 2024, every screening mammogram report include an assessment of Breast Density (BD), which must be communicated to the patient [1]. As the ordering clinician, Family Medicine clinicians will be responsible for advising patients about the implications of identifying patients’ breasts as dense and for providing recommendations about whether additional imaging should be considered based on the reported BD. Here, we briefly discuss BD and offer guidance for providers as they discuss this important topic with their patients.